Cancer Treatment and Research Communications

Our screening does not flag Cancer Treatment and Research Communications. That is not a guarantee of quality — it means the venue is not on Beall's archive (frozen since 2017) and does not match our name-pattern heuristic. It is listed in DOAJ, Scopus, Web of Science, PubMed, which is a positive signal.

Per our venue index, Cancer Treatment and Research Communications appears in: DOAJ, Scopus, Web of Science, PubMed. Index membership changes over time — confirm on the index's own site before relying on it.

Papers in Cancer Treatment and Research Communications are cited about 1.3 times each within two years of publication, and Scimago places it in Q2, with an h-index of 37. Those are the open equivalents: the Clarivate Journal Impact Factor is a proprietary metric we neither compute nor license, so we show the two-year citation rate and Scimago quartile instead — they answer the same question of how heavily the journal is cited. A citation rate is a property of a field as much as of a journal.

Scimago places Cancer Treatment and Research Communications in Q2 for its subject category. Quartiles split the journals in a field into four equal groups by SJR, so Q1 is the most-cited quarter and Q4 the least; Cancer Treatment and Research Communications is cited about 1.3 times per paper over two years, with an h-index of 37. A journal is ranked per subject category, so one spanning several fields can sit in different quartiles depending on the category.

The Web of Science quartile comes from Clarivate's Journal Citation Reports (JCR), a proprietary product we neither license nor compute — so we cannot state a JCR quartile for Cancer Treatment and Research Communications. The open equivalent is its Scimago quartile, Q2, derived from Scopus citation data. Because JCR ranks against Web of Science and Scimago against Scopus, the two can differ, so check Clarivate's site directly if you need the JCR quartile specifically.

Our index records its access status as "gold". Where this is derived from publisher-level signals rather than works-level data it is a heuristic, so confirm on the journal's own site — particularly if an article processing charge matters to you.

Article processing charge (APC): $2,940 per accepted article (DOAJ). Fee waivers are available. The exact charge can vary by article type and any fee waiver, so confirm the current amount on the journal's own site.

Submission to publication for Cancer Treatment and Research Communications takes about ~20 wk — DOAJ self-reported. Treat it as indicative rather than a guarantee: editorial times vary by article type, reviewer availability and season, and a self-reported figure is the journal's own. We do not hold a peer-review acceptance rate for Cancer Treatment and Research Communications.